DE LORENZO, CLAUDIA
 Distribuzione geografica
Continente #
NA - Nord America 2.088
EU - Europa 1.051
AS - Asia 635
AF - Africa 50
SA - Sud America 3
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.830
Nazione #
US - Stati Uniti d'America 2.051
IT - Italia 486
SG - Singapore 314
CN - Cina 250
NL - Olanda 124
IE - Irlanda 106
FI - Finlandia 103
UA - Ucraina 86
DE - Germania 60
CI - Costa d'Avorio 49
SE - Svezia 45
IN - India 43
CA - Canada 36
GB - Regno Unito 23
VN - Vietnam 12
ES - Italia 4
BE - Belgio 3
BR - Brasile 3
FR - Francia 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AU - Australia 2
CH - Svizzera 2
HK - Hong Kong 2
IR - Iran 2
JP - Giappone 2
KR - Corea 2
TR - Turchia 2
AT - Austria 1
EU - Europa 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
PA - Panama 1
PK - Pakistan 1
RO - Romania 1
ZA - Sudafrica 1
Totale 3.830
Città #
Chandler 427
Singapore 255
Naples 166
Amsterdam 123
Jacksonville 112
Ashburn 107
Millbury 96
Princeton 90
Boston 74
Santa Clara 72
Napoli 62
Nanjing 61
Beijing 55
Wilmington 43
Houston 38
Woodbridge 31
Pune 30
Ottawa 28
Des Moines 26
Cagliari 24
Nanchang 22
Falls Church 18
Kronberg 17
Lawrence 17
Shenyang 17
Los Angeles 16
Boardman 15
Helsinki 15
Ercolano 14
Jiaxing 14
Dong Ket 12
Hebei 11
Norwalk 11
Perugia 11
Kunming 10
Dallas 9
Acerra 8
Hyderabad 8
Rome 8
Seattle 8
Tianjin 8
Washington 8
Caserta 7
Changsha 7
Jinan 7
Shanghai 7
Hangzhou 6
Springfield 6
Ann Arbor 5
Toronto 5
Dublin 4
Marano di Napoli 4
Portici 4
Belgrade 3
Bergamo 3
Casavatore 3
Frankfurt am Main 3
Guangzhou 3
Indiana 3
London 3
Munich 3
Redwood City 3
Trentola-Ducenta 3
Villaricca 3
Arezzo 2
Bagheria 2
Bernalda 2
Brussels 2
Capaccio 2
Changchun 2
Chicago 2
Formia 2
Gravelines 2
Indore 2
Ischia 2
Lappeenranta 2
Marano 2
Marcianise 2
Milan 2
New Orleans 2
Orange 2
Padula 2
Phoenix 2
Pozzuoli 2
Quartu Sant'elena 2
Riva Del Garda 2
Sydney 2
São Paulo 2
Tokyo 2
Walnut 2
Winthrop 2
Zhengzhou 2
Afragola 1
Agropoli 1
Aprilia 1
Ariano Irpino 1
Augusta 1
Aversa 1
Bath 1
Brindisi 1
Totale 2.356
Nome #
Nuovi agenti con attività antitumorale nei tumori ErbB2-positivi 73
A novel fully human Antitumor ImmunoRNase targeting ErbB2-positive tumors 61
A novel fully human antitumor ImmunoRNase targeting ErbB2-positive tumors 60
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production 59
A novel ErbB2 epitope targeted by Human antitumor Immunoagents 58
A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. 55
Novel human anti-Claudin 1 monoclonal antibodies inhibit HCV infection and may synergize with anti-SRB1 mAb. 55
A study of the Intracellular Routing of Cytotoxic Ribonucleases 52
A new human antitumor immunoreagent specific for ErbB2 52
A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. 52
A DIMERIC MUTANT OF HUMAN PANCREATIC RIBONUCLEASE WITH SELECTIVE CYTOTOXICITY TOWARD MALIGNANT CELLS 51
Esiste la possibilità di ipotizzare un blocco dei recettori HER con immunoagenti senza effetti cardiotossici? 48
A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity towards malignant cells 47
Novel Human Anti-ErbB2 Immunoagents 47
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 47
Anti-ErbB2 human Immunoagents 46
Biological properties of a human compact anti-ErbB2 antibody. 46
Fusion protein comprising three binding domains to HER2 46
Methods and compositions relating to Anti-nucleolin recombinant immunoagents 46
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin 45
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries 45
A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent 44
Effects of three different anti-ErbB2 antibodies on prostate tumors 44
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer 44
One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1 43
Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. 43
Immunotoxins and ImmunoRNases 42
A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells 42
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 42
Human Antitumor RNases and ImmunoRNases 41
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking 41
Thermodynamic stability of the two isoforms of bovine seminal ribonuclease. 40
Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. 40
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. 40
The molecular basis for the production of an antitumor protein 40
Bovine Seminal RNase: an atypical member of the ribonuclease superfamily 40
A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor. 39
Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. 39
Novel Human Anti-ErbB2 Immunoagents 38
Effects of a human compact anti-ErbB2 antibody on prostate cancer 38
Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model 37
Human anti-nucleolin recombinant immunoagent for cancer therapy 37
Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor 36
Anti-ErbB2 human immunoagents 36
A Novel Human Anti-tumor Dimeric ImmunoRNase 36
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells 36
A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab 35
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. 35
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing 35
Evaluation of the antiproliferative effect of Bifidobacterium longum BB-536 in solid tumor cell lines, co-cultured with murine splenocytes 35
Crystal Structure of the Dimeric unswapped Form of Bovine Seminal Ribonuclease 34
Anti-ErbB2 immunoagents 34
Anti-ErbB2 Human Immunoagents 34
IMMUNORNASES AS ANTITUMOUR AGENTS 34
8th International Meeting on Ribonucleases 34
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. 34
Cardioprotection induced by ranolazine after trastuzumab treatment: the reduction of cardiotoxicity in vitro and in vivo study 34
Novel combinations of human immunomodulatory mAbs lacking cardiotoxic effects for therapy of TNBC 34
Binding of human immunoagents and Herceptin to the ErbB2 receptor 33
Inhibition of cardiomyocytes late I-Na with ranolazine blunts anthracyclines-cardiotoxicity in experimental models in vitro and in vivo 33
Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation. 33
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab 33
Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? 32
Interactions of spike‐rbd of sars‐cov‐2 and platelet factor 4: New insights in the etiopathogenesis of thrombosis 32
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents 31
Antitumor pancreatic-type RNases 31
DOXORUBICIN-INDUCED CARDIOTOXICITY IN MICE IS PREVENTED BY LATE INA INHIBITION WITH RANOLAZINE, WITH IMPROVEMENT IN HEART FUNCTION, FIBROSIS AND APOPTOSIS 31
T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. 31
From immunotoxins to immunoRNases. 30
Human, Anti-ErbB2 Antitumor Immunoagents 30
Fully Human Anti-Cancer ImmunoAgents 30
Trypsin sheds light on the singular case of seminal RNase, a dimer with two quaternary conformations. 29
Effects of protein RNase inhibitor and substrate on the quaternary structures of bovine seminal RNase 29
Effects of a human compact anti-ErbB2 antibody on gastric cancer. 29
RANOLAZINE AT THE END OF TRASTUZUMAB THERAPY PREVENTS LEFT VENTRICULAR DYSFUNCTION: IN VITRO AND IN VIVO STUDY 29
High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand 29
The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. 28
Filamentous Phage Display 28
The singular case of seminal RNase, a dimer with two quaternary conformations, inspected with Trypsin as a conformational probe 28
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents 28
Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody 28
NOVEL HUMAN ANTI-ErbB2 IMMUNOAGENTS 27
A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy 27
NUOVI IMMUNOAGENTI UMANI ANTI-ERBB2 26
Ranolazine blunts anthracyclines-cardiotoxicity in experimental models in vitro and in vivo. 26
Crystallization of multiple forms of bovine seminal ribonuclease in the liganded and unliganded state 25
Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge 25
Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells 25
Differential binding of human immunoagents and Herceptin to the ErbB2 receptor 25
Selective and asymmetric action of trypsin on the dimeric forms of seminal Rnase. 24
First and Second Generation Human anti-ErbB2 Immunoagents 24
COMPARISON OF CARDIOTOXIC EFFECTS OF DIFFERENT ERB-B2 INHIBITORS AND THEIR ASSOCIATED MECHANISMS 24
Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors 24
ImmunoRNases as antitumor agents 23
Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of Ranolazine 23
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling 23
Immunomodulatory mabs as tools to investigate on cis-interaction of pd-1/pd-l1 on tumor cells and to set up methods for early screening of safe and potent combinatorial treatments 23
The antitumor action of seminal ribonuclease and its quaternary conformations 22
Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models 22
New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC 21
Totale 3.655
Categoria #
all - tutte 19.520
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.520


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020130 0 0 0 0 0 1 8 3 4 27 49 38
2020/2021265 6 18 41 22 23 39 19 5 21 23 32 16
2021/2022704 4 4 2 3 12 16 22 34 122 48 194 243
2022/20231.010 124 77 31 86 123 118 5 85 171 116 57 17
2023/2024724 27 112 128 47 30 92 22 107 1 17 91 50
2024/2025509 158 143 37 50 120 1 0 0 0 0 0 0
Totale 4.005